_id
69185d0c3c536f8df2317cd5
Ticker
0QNA.LSE
Name
Basilea Pharmaceutica AG
Exchange
LSE
Address
Hegenheimermattweg 167b, Allschwil, Switzerland, 4123
Country
UK
Sector
Industry
Currency
GBP
Website
https://www.basilea.com
Description
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), and acute bacterial skin and skin structure infections (ABSSSI). The company also has a clinical-stage pipeline of anti-infective assets that include fosmanogepix, a broad-spectrum antifungal in phase 3 development for invasive mold and yeast infections; ceftibuten-ledaborbactam, a phase 3 - ready oral antibiotic for the treatment of complicated urinary tract infections (cUTI); BAL2062, a candidate for invasive aspergillosis currently advancing toward phase 2 clinical development; and BAL2420, a preclinical-stage antibiotic targeting severe Enterobacteriaceae infections. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.
Last Close
51.80764273158
Volume
513
Current Price
52.7
Change
-0.74402136684177
Last Updated
2025-12-29T14:37:17.072Z
Image
https://logo.clearbit.com/www.basilea.com
Ipo Date
-
Market Cap
596308608
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-06-30
Revenue
51980000
Cost Of Revenue
31262000
Gross Profit
20718000
Operating Expenses
8702000
Operating Income
12016000
Interest Expense
1924000
Pretax Income
9672500
Net Income
7901000
Eps
0.5705427225365748
Dividends Per Share
-
Shares Outstanding
10869600
Income Tax Expense
1771500
EBITDA
12549500
Operating Margin
23.11658330126972
Total Other Income Expense Net
-2343500
Cash
128365000
Short Term Investments
-
Receivables
16635000
Inventories
22625000
Total Current Assets
217467000
Property Plant Equipment
17530000
Total Assets
248847000
Payables
9925000
Short Term Debt
4123998
Long Term Debt
-
Total Liabilities
145691000
Equity
103156000
Bs_currency_symbol
-
Depreciation
667000
Change In Working Capital
1055000
Cash From Operations
23056000
Capital Expenditures
160500
Cash From Investing
-414000
Cash From Financing
-14470000
Net Change In Cash
114872000
Cf_currency_symbol
-
PE
-
PB
7.074732333553066
ROE
7.659273333591841
ROA
3.175043299698208
FCF
22895500
Fcf Percent
0.44046748749519044
Piotroski FScore
4
Health Score
60
Deep Value Investing Score
6.5
Defensive Investing Score
6
Dividend Investing Score
3
Economic Moat Investing Score
7.8
Garp Investing Score
3
Growth Investing Score
3
Momentum Investing Score
7.5
Net Net Investing Score
4
Quality Investing Score
6.5
Value Investing Score
5.5
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
51980000
Quarters > 0 > income Statement > cost Of Revenue
31262000
Quarters > 0 > income Statement > gross Profit
20718000
Quarters > 0 > income Statement > operating Expenses
8702000
Quarters > 0 > income Statement > operating Income
12016000
Quarters > 0 > income Statement > interest Expense
1924000
Quarters > 0 > income Statement > pretax Income
9672500
Quarters > 0 > income Statement > net Income
7901000
Quarters > 0 > income Statement > eps
0.5705427225365748
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
13848218
Quarters > 0 > income Statement > income Tax Expense
1771500
Quarters > 0 > income Statement > EBITDA
12549500
Quarters > 0 > income Statement > operating Margin
23.11658330126972
Quarters > 0 > income Statement > total Other Income Expense Net
-2343500
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
128365000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
16635000
Quarters > 0 > balance Sheet > inventories
22625000
Quarters > 0 > balance Sheet > total Current Assets
217467000
Quarters > 0 > balance Sheet > property Plant Equipment
17530000
Quarters > 0 > balance Sheet > total Assets
248847000
Quarters > 0 > balance Sheet > payables
9925000
Quarters > 0 > balance Sheet > short Term Debt
4123998
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
145691000
Quarters > 0 > balance Sheet > equity
103156000
Quarters > 0 > balance Sheet > currency_symbol
-
Quarters > 0 > cash Flow > net Income
7901000
Quarters > 0 > cash Flow > depreciation
667000
Quarters > 0 > cash Flow > change In Working Capital
1055000
Quarters > 0 > cash Flow > cash From Operations
23056000
Quarters > 0 > cash Flow > capital Expenditures
160500
Quarters > 0 > cash Flow > cash From Investing
-414000
Quarters > 0 > cash Flow > cash From Financing
-14470000
Quarters > 0 > cash Flow > net Change In Cash
114872000
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
0.5705427225365748
Quarters > 0 > ratios > PB
7.074732333553066
Quarters > 0 > ratios > ROE
7.659273333591841
Quarters > 0 > ratios > ROA
3.175043299698208
Quarters > 0 > ratios > FCF
22895500
Quarters > 0 > ratios > Piotroski FScore
4
Quarters > 0 > ratios > fcf Percent
0.44046748749519044
Quarters > 0 > health Score
60
Quarters > 1 > quarter
2024-12-31
Quarters > 1 > income Statement > revenue
132250000
Quarters > 1 > income Statement > cost Of Revenue
64108000
Quarters > 1 > income Statement > gross Profit
68142000
Quarters > 1 > income Statement > operating Expenses
16221000
Quarters > 1 > income Statement > operating Income
51921000
Quarters > 1 > income Statement > interest Expense
1823000
Quarters > 1 > income Statement > pretax Income
52935000
Quarters > 1 > income Statement > net Income
56856000
Quarters > 1 > income Statement > eps
4.0937976186764615
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
13888327
Quarters > 1 > income Statement > income Tax Expense
-3921000
Quarters > 1 > income Statement > EBITDA
52975500
Quarters > 1 > income Statement > operating Margin
39.25973534971644
Quarters > 1 > income Statement > total Other Income Expense Net
1014000
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
120700000
Quarters > 1 > balance Sheet > short Term Investments
11000
Quarters > 1 > balance Sheet > receivables
56576000
Quarters > 1 > balance Sheet > inventories
31609000
Quarters > 1 > balance Sheet > total Current Assets
220911000
Quarters > 1 > balance Sheet > property Plant Equipment
19000000
Quarters > 1 > balance Sheet > total Assets
257764000
Quarters > 1 > balance Sheet > payables
11487000
Quarters > 1 > balance Sheet > short Term Debt
4123999
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
176765000
Quarters > 1 > balance Sheet > equity
80999000
Quarters > 1 > balance Sheet > currency_symbol
-
Quarters > 1 > cash Flow > net Income
56856000
Quarters > 1 > cash Flow > depreciation
2935000
Quarters > 1 > cash Flow > change In Working Capital
-2806000
Quarters > 1 > cash Flow > cash From Operations
56443000
Quarters > 1 > cash Flow > capital Expenditures
1243000
Quarters > 1 > cash Flow > cash From Investing
-1272000
Quarters > 1 > cash Flow > cash From Financing
-22000
Quarters > 1 > cash Flow > net Change In Cash
-51621000
Quarters > 1 > cash Flow > currency_symbol
-
Quarters > 1 > ratios > PE
4.0937976186764615
Quarters > 1 > ratios > PB
9.03609714811294
Quarters > 1 > ratios > ROE
70.19345917850838
Quarters > 1 > ratios > ROA
22.05738582579414
Quarters > 1 > ratios > FCF
55200000
Quarters > 1 > ratios > Piotroski FScore
3
Quarters > 1 > ratios > fcf Percent
0.41739130434782606
Quarters > 1 > health Score
71
Quarters > 2 > quarter
2024-06-30
Quarters > 2 > income Statement > revenue
76293000
Quarters > 2 > income Statement > cost Of Revenue
-25427000
Quarters > 2 > income Statement > gross Profit
101720000
Quarters > 2 > income Statement > operating Expenses
92464000
Quarters > 2 > income Statement > operating Income
9256000
Quarters > 2 > income Statement > interest Expense
2521000
Quarters > 2 > income Statement > pretax Income
7325000
Quarters > 2 > income Statement > net Income
20737000
Quarters > 2 > income Statement > eps
1.5003162044640792
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
13821753
Quarters > 2 > income Statement > income Tax Expense
-13412000
Quarters > 2 > income Statement > EBITDA
10154500
Quarters > 2 > income Statement > operating Margin
12.13217464249669
Quarters > 2 > income Statement > total Other Income Expense Net
-1931000
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
62963000
Quarters > 2 > balance Sheet > short Term Investments
6507000
Quarters > 2 > balance Sheet > receivables
28080000
Quarters > 2 > balance Sheet > inventories
31375000
Quarters > 2 > balance Sheet > total Current Assets
155013000
Quarters > 2 > balance Sheet > property Plant Equipment
19412000
Quarters > 2 > balance Sheet > total Assets
188663000
Quarters > 2 > balance Sheet > payables
11471000
Quarters > 2 > balance Sheet > short Term Debt
4123999
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
171877000
Quarters > 2 > balance Sheet > equity
16786000
Quarters > 2 > balance Sheet > currency_symbol
-
Quarters > 2 > cash Flow > net Income
20737000
Quarters > 2 > cash Flow > depreciation
1727000
Quarters > 2 > cash Flow > change In Working Capital
6161000
Quarters > 2 > cash Flow > cash From Operations
17920000
Quarters > 2 > cash Flow > capital Expenditures
467000
Quarters > 2 > cash Flow > cash From Investing
261000
Quarters > 2 > cash Flow > cash From Financing
-13142000
Quarters > 2 > cash Flow > net Change In Cash
56981000
Quarters > 2 > cash Flow > currency_symbol
-
Quarters > 2 > ratios > PE
1.5003162044640792
Quarters > 2 > ratios > PB
43.393684207077335
Quarters > 2 > ratios > ROE
123.53747170260931
Quarters > 2 > ratios > ROA
10.991556373003714
Quarters > 2 > ratios > FCF
17453000
Quarters > 2 > ratios > Piotroski FScore
3
Quarters > 2 > ratios > fcf Percent
0.22876279606254835
Quarters > 2 > health Score
67
Quarters > 3 > quarter
2023-12-31
Quarters > 3 > income Statement > revenue
72729000
Quarters > 3 > income Statement > cost Of Revenue
16798000
Quarters > 3 > income Statement > gross Profit
55931000
Quarters > 3 > income Statement > operating Expenses
73624000
Quarters > 3 > income Statement > operating Income
-17693000
Quarters > 3 > income Statement > interest Expense
9760000
Quarters > 3 > income Statement > pretax Income
-21406000
Quarters > 3 > income Statement > net Income
-21389000
Quarters > 3 > income Statement > eps
-1.7821687966898603
Quarters > 3 > income Statement > dividends Per Share
19091999
Quarters > 3 > income Statement > shares Outstanding
12001669
Quarters > 3 > income Statement > income Tax Expense
-17000
Quarters > 3 > income Statement > EBITDA
-9922000
Quarters > 3 > income Statement > operating Margin
-24.327297226690867
Quarters > 3 > income Statement > total Other Income Expense Net
-3713000
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
12489000
Quarters > 3 > balance Sheet > short Term Investments
51833000
Quarters > 3 > balance Sheet > receivables
27891000
Quarters > 3 > balance Sheet > inventories
26410000
Quarters > 3 > balance Sheet > total Current Assets
152145000
Quarters > 3 > balance Sheet > property Plant Equipment
20552000
Quarters > 3 > balance Sheet > total Assets
173289000
Quarters > 3 > balance Sheet > payables
5847000
Quarters > 3 > balance Sheet > short Term Debt
17515000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
183292000
Quarters > 3 > balance Sheet > equity
-10003000
Quarters > 3 > balance Sheet > currency_symbol
-
Quarters > 3 > cash Flow > net Income
-21389000
Quarters > 3 > cash Flow > depreciation
1724000
Quarters > 3 > cash Flow > change In Working Capital
9179000
Quarters > 3 > cash Flow > cash From Operations
-7619000
Quarters > 3 > cash Flow > capital Expenditures
645000
Quarters > 3 > cash Flow > cash From Investing
-645000
Quarters > 3 > cash Flow > cash From Financing
-40222000
Quarters > 3 > cash Flow > net Change In Cash
-78459000
Quarters > 3 > cash Flow > currency_symbol
GBP
Quarters > 3 > ratios > PE
-1.7821687966898603
Quarters > 3 > ratios > PB
-63.229826681995405
Quarters > 3 > ratios > ROE
213.82585224432668
Quarters > 3 > ratios > ROA
-12.342964642879814
Quarters > 3 > ratios > FCF
-8264000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-0.1136273013515929
Quarters > 3 > health Score
31
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
208543000
Annuals > 0 > income Statement > cost Of Revenue
38681000
Annuals > 0 > income Statement > gross Profit
169862000
Annuals > 0 > income Statement > operating Expenses
108685000
Annuals > 0 > income Statement > operating Income
61177000
Annuals > 0 > income Statement > interest Expense
4344000
Annuals > 0 > income Statement > pretax Income
60260000
Annuals > 0 > income Statement > net Income
77593000
Annuals > 0 > income Statement > eps
5.600344712104765
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
13855040
Annuals > 0 > income Statement > income Tax Expense
-17333000
Annuals > 0 > income Statement > EBITDA
63130000
Annuals > 0 > income Statement > operating Margin
29.33543681638799
Annuals > 0 > income Statement > total Other Income Expense Net
-917000
Annuals > 0 > income Statement > currency_symbol
-
Annuals > 0 > balance Sheet > cash
120700000
Annuals > 0 > balance Sheet > short Term Investments
11000
Annuals > 0 > balance Sheet > receivables
56576000
Annuals > 0 > balance Sheet > inventories
31609000
Annuals > 0 > balance Sheet > total Current Assets
220911000
Annuals > 0 > balance Sheet > property Plant Equipment
19000000
Annuals > 0 > balance Sheet > total Assets
257764000
Annuals > 0 > balance Sheet > payables
11487000
Annuals > 0 > balance Sheet > short Term Debt
2062000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
176765000
Annuals > 0 > balance Sheet > equity
80999000
Annuals > 0 > balance Sheet > currency_symbol
-
Annuals > 0 > cash Flow > net Income
77593000
Annuals > 0 > cash Flow > depreciation
4132000
Annuals > 0 > cash Flow > change In Working Capital
-1654000
Annuals > 0 > cash Flow > cash From Operations
74363000
Annuals > 0 > cash Flow > capital Expenditures
1710000
Annuals > 0 > cash Flow > cash From Investing
-1011000
Annuals > 0 > cash Flow > cash From Financing
-13164000
Annuals > 0 > cash Flow > net Change In Cash
60238000
Annuals > 0 > cash Flow > currency_symbol
-
Annuals > 0 > ratios > PE
5.600344712104765
Annuals > 0 > ratios > PB
9.459174952777193
Annuals > 0 > ratios > ROE
95.79500981493598
Annuals > 0 > ratios > ROA
30.102341676882734
Annuals > 0 > ratios > FCF
72653000
Annuals > 0 > ratios > Piotroski FScore
3
Annuals > 0 > ratios > fcf Percent
0.3483837865572088
Annuals > 0 > health Score
71
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
157634000
Annuals > 1 > income Statement > cost Of Revenue
26794000
Annuals > 1 > income Statement > gross Profit
130840000
Annuals > 1 > income Statement > operating Expenses
111635000
Annuals > 1 > income Statement > operating Income
19205000
Annuals > 1 > income Statement > interest Expense
11202000
Annuals > 1 > income Statement > pretax Income
10461000
Annuals > 1 > income Statement > net Income
10451000
Annuals > 1 > income Statement > eps
0.8606550053170213
Annuals > 1 > income Statement > dividends Per Share
57305000
Annuals > 1 > income Statement > shares Outstanding
12143077
Annuals > 1 > income Statement > income Tax Expense
10000
Annuals > 1 > income Statement > EBITDA
23185000
Annuals > 1 > income Statement > operating Margin
12.183285331844653
Annuals > 1 > income Statement > total Other Income Expense Net
-8744000
Annuals > 1 > income Statement > currency_symbol
-
Annuals > 1 > balance Sheet > cash
59900000
Annuals > 1 > balance Sheet > short Term Investments
51833000
Annuals > 1 > balance Sheet > receivables
27891000
Annuals > 1 > balance Sheet > inventories
26410000
Annuals > 1 > balance Sheet > total Current Assets
152145000
Annuals > 1 > balance Sheet > property Plant Equipment
20552000
Annuals > 1 > balance Sheet > total Assets
173289000
Annuals > 1 > balance Sheet > payables
5847000
Annuals > 1 > balance Sheet > short Term Debt
17515000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
183292000
Annuals > 1 > balance Sheet > equity
-10003000
Annuals > 1 > balance Sheet > currency_symbol
-
Annuals > 1 > cash Flow > net Income
10451000
Annuals > 1 > cash Flow > depreciation
3477000
Annuals > 1 > cash Flow > change In Working Capital
-5225000
Annuals > 1 > cash Flow > cash From Operations
14245000
Annuals > 1 > cash Flow > capital Expenditures
1034000
Annuals > 1 > cash Flow > cash From Investing
-1034000
Annuals > 1 > cash Flow > cash From Financing
-57305000
Annuals > 1 > cash Flow > net Change In Cash
-44245000
Annuals > 1 > cash Flow > currency_symbol
GBP
Annuals > 1 > ratios > PE
0.8606550053170213
Annuals > 1 > ratios > PB
-67.13107648705387
Annuals > 1 > ratios > ROE
-104.47865640307907
Annuals > 1 > ratios > ROA
6.030965612358545
Annuals > 1 > ratios > FCF
13211000
Annuals > 1 > ratios > Piotroski FScore
3
Annuals > 1 > ratios > fcf Percent
0.0838080617125747
Annuals > 1 > health Score
44
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
147765000
Annuals > 2 > income Statement > cost Of Revenue
26803000
Annuals > 2 > income Statement > gross Profit
120962000
Annuals > 2 > income Statement > operating Expenses
104619000
Annuals > 2 > income Statement > operating Income
18543000
Annuals > 2 > income Statement > interest Expense
9848000
Annuals > 2 > income Statement > pretax Income
12102000
Annuals > 2 > income Statement > net Income
12147000
Annuals > 2 > income Statement > eps
1.0170364276878057
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
11943525
Annuals > 2 > income Statement > income Tax Expense
-45000
Annuals > 2 > income Statement > EBITDA
26210000
Annuals > 2 > income Statement > operating Margin
12.548979799005178
Annuals > 2 > income Statement > total Other Income Expense Net
-6441000
Annuals > 2 > income Statement > currency_symbol
GBP
Annuals > 2 > balance Sheet > cash
36567000
Annuals > 2 > balance Sheet > short Term Investments
50000000
Annuals > 2 > balance Sheet > receivables
61704000
Annuals > 2 > balance Sheet > inventories
24244000
Annuals > 2 > balance Sheet > total Current Assets
175364000
Annuals > 2 > balance Sheet > property Plant Equipment
21571000
Annuals > 2 > balance Sheet > total Assets
220848000
Annuals > 2 > balance Sheet > payables
191000
Annuals > 2 > balance Sheet > short Term Debt
39455000
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
241563000
Annuals > 2 > balance Sheet > equity
-20715000
Annuals > 2 > balance Sheet > currency_symbol
GBP
Annuals > 2 > cash Flow > net Income
12147000
Annuals > 2 > cash Flow > depreciation
3097000
Annuals > 2 > cash Flow > change In Working Capital
-11723000
Annuals > 2 > cash Flow > cash From Operations
7056000
Annuals > 2 > cash Flow > capital Expenditures
3303000
Annuals > 2 > cash Flow > cash From Investing
91649000
Annuals > 2 > cash Flow > cash From Financing
-45246000
Annuals > 2 > cash Flow > net Change In Cash
53614000
Annuals > 2 > cash Flow > currency_symbol
GBP
Annuals > 2 > ratios > PE
1.0170364276878057
Annuals > 2 > ratios > PB
-31.883993845039825
Annuals > 2 > ratios > ROE
-58.63866763215062
Annuals > 2 > ratios > ROA
5.50016300804173
Annuals > 2 > ratios > FCF
3753000
Annuals > 2 > ratios > Piotroski FScore
3
Annuals > 2 > ratios > fcf Percent
0.025398436706933307
Annuals > 2 > health Score
37
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
148122000
Annuals > 3 > income Statement > cost Of Revenue
24072000
Annuals > 3 > income Statement > gross Profit
124050000
Annuals > 3 > income Statement > operating Expenses
122878000
Annuals > 3 > income Statement > operating Income
1187000
Annuals > 3 > income Statement > interest Expense
8151000
Annuals > 3 > income Statement > pretax Income
-6794000
Annuals > 3 > income Statement > net Income
-6831000
Annuals > 3 > income Statement > eps
-0.5847470140965034
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
11681975
Annuals > 3 > income Statement > income Tax Expense
37000
Annuals > 3 > income Statement > EBITDA
6723000
Annuals > 3 > income Statement > operating Margin
0.8013664411768676
Annuals > 3 > income Statement > total Other Income Expense Net
-7981000
Annuals > 3 > income Statement > currency_symbol
GBP
Annuals > 3 > balance Sheet > cash
54953000
Annuals > 3 > balance Sheet > short Term Investments
95000000
Annuals > 3 > balance Sheet > receivables
64447000
Annuals > 3 > balance Sheet > inventories
22783000
Annuals > 3 > balance Sheet > total Current Assets
241066000
Annuals > 3 > balance Sheet > property Plant Equipment
2923000
Annuals > 3 > balance Sheet > total Assets
247267000
Annuals > 3 > balance Sheet > payables
10617000
Annuals > 3 > balance Sheet > short Term Debt
124401000
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
305874000
Annuals > 3 > balance Sheet > equity
-58607000
Annuals > 3 > balance Sheet > currency_symbol
GBP
Annuals > 3 > cash Flow > net Income
-6831000
Annuals > 3 > cash Flow > depreciation
2454000
Annuals > 3 > cash Flow > change In Working Capital
-31787000
Annuals > 3 > cash Flow > cash From Operations
-32020000
Annuals > 3 > cash Flow > capital Expenditures
860000
Annuals > 3 > cash Flow > cash From Investing
3575000
Annuals > 3 > cash Flow > cash From Financing
16640000
Annuals > 3 > cash Flow > net Change In Cash
-654000
Annuals > 3 > cash Flow > currency_symbol
GBP
Annuals > 3 > ratios > PE
-0.5847470140965034
Annuals > 3 > ratios > PB
-11.02279962291194
Annuals > 3 > ratios > ROE
11.655604279352296
Annuals > 3 > ratios > ROA
-2.762600751414463
Annuals > 3 > ratios > FCF
-32880000
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-0.22197917932515088
Annuals > 3 > health Score
23
Valuation > metrics > PE
0.5705427225365748
Valuation > metrics > PB
7.074732333553066
Valuation > final Score
40
Valuation > verdict
20.8% Overvalued
Profitability > metrics > ROE
7.659273333591841
Profitability > metrics > ROA
3.633194921528324
Profitability > metrics > Net Margin
0.15200076952674105
Profitability > final Score
49
Profitability > verdict
Weak
Risk > metrics > Debt Equity
1.412336655163054
Risk > metrics > Interest Coverage
6.245322245322245
Risk > final Score
55
Risk > verdict
High
Liquidity > metrics > Current Ratio
15.479182216411449
Liquidity > metrics > Quick Ratio
13.868747080752662
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
40
Prev Valuations > 1
40
Prev Valuations > 2
50
Prev Profitabilities > 0
100
Prev Profitabilities > 1
100
Prev Profitabilities > 2
40
Prev Risks > 0
58
Prev Risks > 1
21
Prev Risks > 2
23
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T22:57:34.924Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-02-17
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
AfterMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), and acute bacterial skin and skin structure infections (ABSSSI). The company also has a clinical-stage pipeline of anti-infective assets that include fosmanogepix, a broad-spectrum antifungal in phase 3 development for invasive mold and yeast infections; ceftibuten-ledaborbactam, a phase 3 - ready oral antibiotic for the treatment of complicated urinary tract infections (cUTI); BAL2062, a candidate for invasive aspergillosis currently advancing toward phase 2 clinical development; and BAL2420, a preclinical-stage antibiotic targeting severe Enterobacteriaceae infections. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.
Stock Price
£0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/A(Last Updated 2025-06-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very High
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Basilea Pharmaceutica AG
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
—
Date
—
EPS Actual
—
EPS Estimate
—
EPS Difference
—
Surprise Percent
undefined%
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
£ 0
Cost Of Revenue
£ 0
Gross Profit
£ 0
Operating Expenses
£ 0
Operating Income
£ 0
Interest Expense
£ 0
Pretax Income
£ 0
Net Income
£ 0
Income Tax Expense
£ 0
EBITDA
£ 0
Total Other Income Expense Net
£ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-06-30)
Cash
£ 0
Short Term Investments
£ 0
Receivables
£ 0
Inventories
£ 0
Total Current Assets
£ 0
Property Plant Equipment
£ 0
Total Assets
£ 0
Payables
£ 0
Short Term Debt
£ 0
Long Term Debt
£ 0
Total Liabilities
£ 0
Equity
£ 0
(Last Updated 2025-06-30)
Net Income
£ 0
Depreciation
£ 0
Change In Working Capital
£ 0
Cash From Operations
£ 0
Capital Expenditures
£ 0
Cash From Investing
£ 0
Cash From Financing
£ 0
Net Change In Cash
£ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.